Join the club for FREE to access the whole archive and other member benefits.

Juvenescence

Developing therapies against different aging related diseases

Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.

Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life. 

By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.

Juvenescence Executive Team

  • Greg Bailey, Co-founder, Executive Chairman
  • Jim Mellon, Co-founder, Deputy Chairman
  • Declan Doogan, Co-founder, Board Member
  • Richard Marshall, Chief Executive Officer
  • Gillian Dines, Chief Science Officer
  • Steve Felstead, Chief Medical Officer
  • Jeff Madwed, Senior Project Lead
  • Rosalba Perrone, Senior Research Scientist
  • Kersten Small, Project Leader
  • David Gill, Chief Financial Officer
  • Alexander Pickett, Managing Director

Visit website: https://www.juvlabs.com/

 juvlabs

 juvenescence1

 juvlabs

Details last updated 04-May-2019

Juvenescence News

UK biotech Juvenescence secures over $150m to develop therapies

UK biotech Juvenescence secures over $150m to develop therapies

Endpoints News - 21-May-2025

Juvenescence expands pipeline and UAE presence with new funding to tackle age-related diseases

AI alliance to redefine the future of ageing and therapeutics

AI alliance to redefine the future of ageing and therapeutics

Juvenescence - 16-Apr-2025

M42 and Juvenescence join forces to accelerate precision medicine and longevity

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years

Summary of Jim Mellon presentation at Longevity Med Summit

Summary of Jim Mellon presentation at Longevity Med Summit

Live Forever Club - 19-May-2023

Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry

AgeX credit running out with substantial doubt it can continue

AgeX credit running out with substantial doubt it can continue

FierceBiotech - 15-Aug-2022

Let's hope their research is either successful for the company or its successors


Display all news

Mentioned in this Resource

Alexander Pickett

Managing Director at Juvenescence

David Gill

Chief Financial Officer at Juvenescence

Declan Doogan

Co-founder of Juvenescence

Gillian Dines

Chief Science Officer at Juvenescence

Gregory Bailey

CEO at Juvenescence and chairman of Portage Biotech

Jeff Madwed

Senior Project Lead at Juvenescence

Jim Mellon

British entrepreneur, author and philanthropist with interests across a number of industries

Richard Marshall

Chief Executive Officer at Juvenescence

Steve Felstead

Chief Medical Officer at Juvenescence

Juvenescence is also referenced in the following:

BHB Therapeutics

Developing preventative medicines for age-related disease using ketone bodies

Jeff Madwed

Senior Project Lead at Juvenescence

Napa Therapeutics

Focused on a novel target linked to one of the fundamental processes of aging

Selah Therapeutics

Company focused on novel ketone-based therapies for the treatment of heart diseases

Juvenescence Creations

Investing in the Future of Longevity – the Ketone Chapter

10-May-2022

Juvenescence webinar about the latest research and developments on future of longevity investment

Other people at Juvenescence

David Roblin

Chief Operating Officer and CEO of Therapeutics Division at Juvenescence

Colin Watts

CEO at Juvenescence Life.

Ellen Donnelly

Chief Executive Officer of the Epigenetics Division of Juvenescence Limited

Topics mentioned on this page:
Ageing Research